CANCER SECOND OPINION AT
TATA MEMORIAL CENTRE MUMBAI
India's national cancer centre — where 70,000 new patients are seen annually by subspecialist oncologists across every major tumour type, at government-regulated costs.
analyticsAt a Glance
- check_circleTata Memorial Centre is India's premier national cancer hospital, established in 1941 and affiliated with the Homi Bhabha National Institute
- check_circleOver 70,000 new cancer registrations per year — the highest volume cancer centre in Asia outside China
- check_circleSubspecialist depth across head and neck, gastrointestinal, gynaecological, haematological, paediatric, and rare tumours
- check_circleCancerFax facilitates structured second opinion access at TMC for international and out-of-city patients
About Tata Memorial Centre: Why It Is India's First Choice for Cancer Second Opinions
Tata Memorial Centre (TMC) Mumbai is India's oldest and largest dedicated cancer centre — a government-funded autonomous institution under the Department of Atomic Energy. Founded in 1941, TMC combines a high-volume clinical programme with one of Asia's most active oncology research departments, producing treatment outcome data and clinical trial evidence that directly shapes Indian and international oncology practice.
“Volume is expertise — and no cancer centre in India comes close to Tata Memorial's depth of subspecialist experience across every major tumour type.”
Clinical Scale and Subspecialisation
TMC's clinical departments span surgical oncology, medical oncology, radiation oncology, haematology, paediatric oncology, nuclear medicine, and pathology — each staffed by subspecialists who see exclusively their tumour type in high volumes. The head and neck, gastrointestinal, and haematology programmes are internationally recognised.
Research and Trial Access
TMC is India's primary site for oncology clinical trials — including cooperative group studies with ECOG-ACRIN, EORTC, and domestic ICMR-funded trials. Second opinion patients who are identified as trial-eligible can be enrolled directly, giving access to novel agents not available in routine care.
Tata Memorial Centre: Key Scale Numbers
The scale of TMC's clinical programme defines its subspecialist expertise — the more cases a centre sees, the more reliable its pattern recognition across rare and complex presentations.
- 70,000+New cancer registrations per yearTMC registers over 70,000 new cancer patients annually — making it the highest-volume cancer centre in India and among the highest-volume in Asia, providing a deep evidence base for complex and rare case reviews.
- 80+Subspecialist oncology departments and unitsTMC is structured into disease-specific units covering over 80 oncological subspecialties — ensuring that second opinion cases are reviewed by experts who focus exclusively on the relevant tumour type.
- ~60%Patients who travel from outside Maharashtra for careThe majority of TMC patients come from outside Mumbai — from across India and from neighbouring countries including Bangladesh, Nepal, and Sri Lanka — making it an established hub for regional referral and second opinions.
TMC Subspecialty Strengths by Cancer Type
TMC's clinical reputation varies across tumour types — these are the areas where its depth of subspecialist experience and case volume make it the strongest second opinion destination in India.
| Cancer Type | TMC Programme Strength | Why TMC Is the Right Centre |
|---|---|---|
| Head and neck cancers | National reference centre | Highest volume head and neck programme in India; subspecialist surgical, radiation, and medical oncology teams; complex reconstruction capability |
| Gastrointestinal cancers | Exceptionally strong | Gastric, oesophageal, colorectal, hepatobiliary, and pancreatic oncology — all with dedicated disease-specific units and active trial enrolment |
| Haematological malignancies | National reference centre | Leukaemia, lymphoma, myeloma, and MDS — full BMT programme; among the largest allogeneic transplant programmes in Asia |
| Gynaecological cancers | Very strong | High-volume cervical, ovarian, and endometrial oncology; one of India's principal centres for gynaecological cancer subspecialisation |
| Paediatric oncology | Among Asia's best | TMC's KDAH paediatric unit is India's most experienced paediatric cancer centre — rare tumours, medulloblastoma, retinoblastoma, and leukaemia |
| Soft tissue sarcoma | Strong | Dedicated musculoskeletal and sarcoma unit; high volume enables reliable subspecialist pathology review — critical for this diagnostically challenging tumour type |
| Breast cancer | Very strong | High volume; strong surgical oncology and radiation programme; molecular subtype-directed treatment; access to contemporary CDK4/6 inhibitor trials |
How to Get a TMC Second Opinion Through CancerFax
CancerFax manages the end-to-end process — from records preparation to appointment coordination and logistics — making TMC accessible to patients from outside India or outside Maharashtra.
- 1
Submit Records to CancerFax
Patient submits all available records — pathology reports, imaging on CD or cloud, molecular testing results, prior treatment records. CancerFax reviews for completeness and identifies any gaps before forwarding to TMC.
- 2
Records Translation and Preparation
Non-English records (Arabic, Bengali, Urdu, French, etc.) are medically translated by CancerFax. Records are compiled into a structured TMC referral package with a concise clinical summary.
- 3
Appointment Booking with TMC Subspecialist
CancerFax coordinates appointment booking with the relevant TMC disease-specific unit — head and neck unit, GI oncology, haematology, etc. Priority review slots are arranged for CancerFax-referred patients.
- 4
Travel and Logistics Support for Mumbai
For patients travelling from outside India, CancerFax assists with Indian medical visa, flight guidance, accommodation near TMC in Parel, and local transport coordination.
- 5
In-Person TMC Consultation
Patient attends TMC for in-person consultation with the subspecialist. CancerFax provides a bilingual coordinator for non-English-speaking patients. Consultation includes clinical examination, records review, and treatment recommendation.
- 6
Written Report and Follow-up
TMC issues a formal written second opinion report. CancerFax coordinates translation of the report into the patient's language where required and assists with follow-up communication for treatment planning.
TMC vs Private Hospitals for a Cancer Second Opinion in India
Both TMC and India's leading private hospitals (Apollo, Fortis, Manipal) are strong second opinion destinations — but they differ meaningfully in their strengths and the patient experience.
Tata Memorial Centre (Government)
- Deepest subspecialist expertise by volumeTMC's disease-specific units see the highest volume of complex and rare cancers in India — the depth of subspecialist expertise is unmatched, particularly for rare tumours, sarcomas, and paediatric oncology.
- Government-regulated, lower costsTMC operates under government pricing — consultation fees and treatment costs are significantly lower than private hospitals, making specialist access affordable even for patients without insurance.
- National clinical trial accessTMC is India's primary clinical trial site — patients seen at TMC have access to the broadest range of open trials in the country, including cooperative group studies unavailable elsewhere.
Apollo / Fortis / Manipal (Private)
- Shorter wait times and more accessible appointmentsPrivate hospitals typically offer faster appointments and a more streamlined patient experience for paying and international patients — important when speed of access is critical.
- Superior infrastructure for international patientsApollo and Fortis have dedicated international patient departments with English-speaking coordinators, VIP services, and established international insurance billing systems.
- Strong for common cancers with standard protocolsFor breast, lung, and prostate cancer treated on standard protocols, private hospital experience is fully adequate — and the patient experience infrastructure is better suited to international patients.
Frequently Asked Questions
Common questions from patients considering a Tata Memorial Centre second opinion through CancerFax.
About TMC and the Access Process
Can international patients get a second opinion at TMC?
Yes — TMC sees patients from across South Asia and beyond. The hospital has a foreign nationals cell that handles registration for international patients. CancerFax manages the full process including appointment booking, medical visa documentation, and on-ground coordination in Mumbai — making TMC fully accessible to international patients without navigating the process independently.
How long does a TMC second opinion take?
The consultation itself typically requires 1–3 days at TMC — including review appointments, any additional investigations the TMC team requests, and the formal opinion discussion. For patients who can submit records in advance through CancerFax, the TMC team reviews records before the visit, making the consultation more efficient. The formal written opinion is typically issued within 1–2 weeks of the visit.
Is TMC appropriate for rare tumours and complex cases?
Yes — this is where TMC's subspecialist depth is most valuable. For rare tumours including soft tissue sarcoma, rare head and neck tumours, neuroendocrine tumours, and rare haematological malignancies, TMC's volume and subspecialist experience makes it one of the strongest second opinion destinations in Asia. CancerFax will identify the specific TMC unit most relevant to your case.
What languages does CancerFax support for TMC second opinions?
CancerFax provides medical translation and interpreter support for Arabic, Bengali, Urdu, French, Swahili, and other major languages for TMC-bound patients. The TMC clinical team works in English and Hindi — CancerFax bridges all language gaps throughout the process.
More from the Cancer Second Opinion Resource Library
Explore related second opinion guides — from Apollo India to China's specialist centres.
- ↑ Cancer Second Opinion — Complete Guide
- Getting a Cancer Second Opinion at Apollo Hospitals India
- Cancer Second Opinions in China: Zhongshan, Fudan, and Sun Yat-sen
- Getting a Second Opinion at MD Anderson: The International Patient Process
- What Is a Cancer Second Opinion and Why Should Every Patient Consider One?
- Remote vs In-Person Cancer Second Opinions: How to Decide
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access a Tata Memorial Centre Second Opinion Through CancerFax
CancerFax coordinates second opinion access at Tata Memorial Centre — managing records preparation, appointment booking with the relevant subspecialist department, translation of non-English records, and logistical support for patients travelling to Mumbai from outside India.
This content is for informational purposes only and does not constitute medical advice. CancerFax is an access facilitation service — clinical decisions remain with the treating oncologist at TMC.